Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial.
Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial.
复制标题
DOI：
10.1186/s12917-016-0676-x
复制
发表时间：
2016-03-10
影响因子：
2.6
通讯作者：
Cerón J
中科院分区：
文献类型：
--
作者：
Segarra S;Martínez-Subiela S;Cerdà-Cuéllar M;Martínez-Puig D;Muñoz-Prieto A;Rodríguez-Franco F;Rodríguez-Bertos A;Allenspach K;Velasco A;Cerón J
犬炎症性肠病（IBD）是一种病因不明的慢性肠病，尽管微生物群失调，遗传易感性以及饮食和/或环境因素被假设参与其发病机制。由于目前的一些疗法与严重的副作用有关，因此需要新的治疗方式。开发了一种用于长期管理犬IBD的新型口服补充剂，其含有硫酸软骨素（CS）和益生元（抗性淀粉、β-葡聚糖和甘露寡糖），以靶向肠道炎症和氧化应激，并恢复正常生物状态，而不会表现出任何副作用。这项在IBD犬中进行的双盲、随机、安慰剂对照试验旨在评估180天这种补充剂与水解饮食一起给药对临床体征、肠道组织学、肠道微生物群以及炎症和氧化应激的血清生物标志物的影响。27只客户拥有的活检证实的IBD犬被纳入研究，转换为相同的水解饮食，并分为两组之一：补充剂和安慰剂。最初，对于任何研究参数，组间均无显著差异（p > 0.05）。最终数据分析（补充剂：n = 9;安慰剂：n = 10）显示治疗后两组犬IBD活动指数（CIBDAI）评分均显著降低（p < 0.001）。治疗后，仅在补充剂组中观察到组织学评分显著降低（1.53倍; p < 0.01）。当各组进行比较时，补充剂组在治疗60天后显示出显著更高的血清胆固醇（p < 0.05）和对氧磷酶-1（PON 1）水平（p < 0.01），而安慰剂组在120天后显示出显著降低的血清总抗氧化能力（TAC）水平（p < 0.05）。在任何时间点，CIBDAI、WSAVA组织学评分和通过PCR-限制性片段长度多态性（PCR-RFLP）评价的粪便微生物群在组间均无显著差异。任何组均未报告副作用。在180天内将补充剂与水解饮食联合给药是安全的，并诱导了选定血清生物标志物的改善，可能表明疾病活动减少。这项研究可能动力不足，因此需要进行更大规模的研究，以证明这种补充剂对肠道组织学和CIBDAI的饮食治疗的补充作用。
Canine inflammatory bowel disease (IBD) is a chronic enteropathy of unknown etiology, although microbiome dysbiosis, genetic susceptibility, and dietary and/or environmental factors are hypothesized to be involved in its pathogenesis. Since some of the current therapies are associated with severe side effects, novel therapeutic modalities are needed. A new oral supplement for long-term management of canine IBD containing chondroitin sulfate (CS) and prebiotics (resistant starch, β-glucans and mannaoligosaccharides) was developed to target intestinal inflammation and oxidative stress, and restore normobiosis, without exhibiting any side effects. This double-blinded, randomized, placebo-controlled trial in dogs with IBD aims to evaluate the effects of 180 days administration of this supplement together with a hydrolyzed diet on clinical signs, intestinal histology, gut microbiota, and serum biomarkers of inflammation and oxidative stress. Twenty-seven client-owned biopsy-confirmed IBD dogs were included in the study, switched to the same hydrolyzed diet and classified into one of two groups: supplement and placebo. Initially, there were no significant differences between groups (p > 0.05) for any of the studied parameters. Final data analysis (supplement: n = 9; placebo: n = 10) showed a significant decrease in canine IBD activity index (CIBDAI) score in both groups after treatment (p < 0.001). After treatment, a significant decrease (1.53-fold; p < 0.01) in histologic score was seen only in the supplement group. When groups were compared, the supplement group showed significantly higher serum cholesterol (p < 0.05) and paraoxonase-1 (PON1) levels after 60 days of treatment (p < 0.01), and the placebo group showed significantly reduced serum total antioxidant capacity (TAC) levels after 120 days (p < 0.05). No significant differences were found between groups at any time point for CIBDAI, WSAVA histologic score and fecal microbiota evaluated by PCR-restriction fragment length polymorphism (PCR-RFLP). No side effects were reported in any group. The combined administration of the supplement with hydrolyzed diet over 180 days was safe and induced improvements in selected serum biomarkers, possibly suggesting a reduction in disease activity. This study was likely underpowered, therefore larger studies are warranted in order to demonstrate a supplemental effect to dietary treatment of this supplement on intestinal histology and CIBDAI.